Transcode Therapeutics ROE
The Return on Equity (ROE) of Transcode Therapeutics (RNAZ) as of Sep 3, 2026 is 831.51 %. In the previous year, Return on Equity (ROE) was -1,130.17 % — a change of -173.57% (higher).
Get this data via API
Financial Data API
ROE
831.51 %
YoY
-173.57%
Last updated:
In 2026, Transcode Therapeutics's return on equity (ROE) was 831.51 %, a -173.57% increase from the -1,130.17 % ROE in the previous year.
The Transcode Therapeutics ROE history
3 Years
10 Years
25 Years
Max
| YEAR | ROE | YoY |
|---|---|---|
| 831.51 % | -173.57% | |
| -1,130.17 % | +108.53% | |
| -541.96 % | +1,515.89% | |
| -33.54 % | -148.77% | |
| 68.78 % | +25.73% | |
| 54.70 % | -39.19% | |
| 89.96 % | — |
Transcode Therapeutics Stock analysis
ROE Details
Decoding Transcode Therapeutics's Return on Equity (ROE)
Transcode Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Transcode Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Transcode Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Transcode Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Transcode Therapeutics stock
Return on Equity (ROE) of Transcode Therapeutics is 831.51 % in 2026.
Return on Equity (ROE) of Transcode Therapeutics changed from -1,130.17 % to 831.51 %, representing a -173.57% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Return on Equity (ROE) Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Transcode Therapeutics with sector peers and the industry average to assess whether it is attractive.
To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).
Profitability — Transcode Therapeutics
All Key Metrics — Transcode Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth